Tango Therapeutics, Inc.

NASDAQ:TNGX

Biotechnology

Healthcare
$22.71 -10.03%

-$3.24 today

Market cap
$3.85B
Beta
1.19
P/E (TTM)
-38.9
EPS (TTM)
-$0.75
52W Low $4.60High $34.39

Volume 1.81M

Average 3.67M

Big Five Numbers

Tango Therapeutics, Inc. growth analysis

Start with the long-run numbers that show whether TNGX compounds: return on capital and growth in sales, earnings, equity, and free cash flow.

Big Five Numbers

CAGR by period · ROIC shows average

Metric 10yr 5yr3yr1yr
EPS
N/AN/AN/AN/A
Revenue
N/AN/A+35.9%+48.3%
Equity
N/AN/A+1.6%+63.1%
Cash
N/AN/A+23.3%+61.5%
ROIC
N/A-30.9%-37.7%-29.3%

Analysis

Latest growth is strongest in Equity at +63.1% and weakest in ROIC at -29.3%. Three-year average ROIC is -37.7%, which helps show whether that growth is being earned efficiently.

Growth analysis

Is growth accelerating or fading?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/A+35.9%
+68.1% (5yr)5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Recent growth has been strongest in Revenue at +35.9% over three years. Forward estimates point to Revenue at +68.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Revenue segments

Where does the growth come from?

Break revenue down by product and geography to see which parts of the business drive the trend.

Revenue by segment

Where TNGX earns its revenue, as reported in company filings

  • Collaboration Revenue
  • License Revenue
Revenue by segment for FY2025
Segment · FY2025 Revenue Share YoY
Collaboration Revenue$62.38M100.0%+108.2%

Figures in USD.

Free cash flow

Does growth turn into cash?

Check whether reported growth converts into free cash flow after capital spending.

Free Cash Flow

Net Income to FCF bridge

Cash Flow Statement

FY2025

= Net Income-$101.6M
+ D&A$2.3M
+ Stock-Based Comp$26.4M
+ Deferred Tax$0
- Working Capital-$67.2M
+ Other Non-Cash$1.2M
= Operating Cash Flow-$138.9M
- Capex-$1.0M
= Free Cash Flow-$139.9M

Analysis

FY2025 free cash flow is -$139.9M. FCF conversion is 137.7% of net income. Operating cash flow was -$138.9M, with capex of -$1.0M. The largest bridge item is Working Capital at -$67.2M.

Price targets

What do analysts expect from the price?

Compare the current price with the low, average, and high analyst targets.

Wall Street price targets

1-year price history with analyst consensus target

Growth

Unlock analyst target range

Sign in free to see low, average, high targets and implied upside for TNGX.

Sign in free

Analyst ratings

How do analysts rate the stock?

Review the buy, hold, and sell split and recent upgrades and downgrades.

Analyst ratings

Buy, hold, and sell recommendations and recent rating changes

Unlock analyst ratings

Sign in free to see the buy/hold/sell breakdown and recent rating changes for TNGX.

Sign in free

Competitor growth

How does Tango Therapeutics, Inc. grow against peers?

Compare historical and forecast growth with similar companies.

Competitor Growth

Peer CAGR comparison & forward estimates

CompanyMarket Cap10yr5yr3yrFwd

Revolution Medicines, Inc.

RVMD

$37.26B———
—10 analysts

Erasca, Inc.

ERAS

$5.48B———
—3 analysts

Relay Therapeutics, Inc.

RLAY

$4.00B—-28.6%+123.2%
+97.7% (5yr)4 analysts

IDEAYA Biosciences, Inc.

IDYA

$3.08B—+62.1%+62.5%
+31.8% (5yr)6 analysts

Nurix Therapeutics, Inc.

NRIX

$1.69B—+36.3%+29.5%
+31.3% (5yr)2 analysts

Nuvation Bio Inc.

NUVB

$1.40B———
+64.1% (5yr)5 analysts

C4 Therapeutics, Inc.

CCCC

$362.43M—+1.6%+5.0%
+135.8% (5yr)5 analysts

Prelude Therapeutics Incorporated

PRLD

$275.32M———
+52.5% (5yr)1 analysts

Foghorn Therapeutics Inc.

FHTX

$124.12M—+135.1%+17.1%
+21.4% (5yr)3 analysts

Acrivon Therapeutics, Inc. Common Stock

ACRV

$62.14M———
—2 analysts

Questions

Growth questions

Common questions about TNGX's growth, answered from reported and forecast figures.

Is TNGX growing revenue?

Revenue grew 48.3% year over year, from $42.07M to $62.38M.

Is TNGX turning growth into profit?

The latest net margin is -162.9%, which shows how much revenue became net income.